TRIM21 and systemic lupus erythematosus: On the contrary, the same comparison in anti-Ro52+/anti-Ro60– patients among various diseases showed that reactivity against Ro52-1 was less frequent in SSc compared to SLE (0/28 [0%] vs. 6/10, [60%], p = 0.001); Similarly, reactivity against Ro52-4 was less frequent in SSc than in SLE (5/28 [17.9%] vs. 6/10 [60%], p = 0.019) patients.